- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04563702
Safety and Immunogenicity Trial of an Oral SARS-CoV-2 Vaccine (VXA-CoV2-1) for Prevention of COVID-19 in Healthy Adults and Boost (VXA-CoV2-1.1-S) at 1 Year Post Initial Vaccination in Subset of Subjects
A Phase 1 Open-Label, Dose-Ranging Trial to Determine the Safety and Immunogenicity of an Adenoviral-Vector Based Vaccine (VXA-CoV2-1) Expressing a SARS-CoV-2 Antigen and dsRNA Adjuvant Administered Orally to Healthy Adult Volunteers VXA-CoV2-1.1-S Boost Substudy: Boost at 1 Year Post Initial Vaccination With an Adenoviral-Vector Based Vaccine VXA-CoV2-1.1-S Expressing a SARS-CoV-2 S Protein in a Subset of Subjects
Study Overview
Detailed Description
This is an open-label, dose-ranging trial to determine the safety and immunogenicity of an orally administered adenoviral-vector based vaccine (VXA-COV2-1) expressing a SARS-CoV-2 antigen and dsRNA adjuvant. Post screening activities, healthy adult volunteers aged 18 - 54 yrs old, inclusive, will be enrolled into the study. Participants will receive an oral dose of vaccine at Days 1 and a subject will also receive a second dose at Day 29; total study period will last ~ 2 months during the active phase, with a total 12 month safety follow-up period post last vaccination. Safety, reactogenicity and immunogenicity assessments will be performed at set times during the study active and follow-up periods. Subjects will be monitored for symptoms of COVID-19 throughout the duration of the study follow-up period.
Approximately 10 healthy male and female adult volunteers 18 to 54 years old who were enrolled in the main study will be included in a boost extension substudy for an additional 12 months from dosing for a total participation period of 24-25 months.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
California
-
Cypress, California, United States, 90630
- WCCT
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female between the ages of 18 to 54 years, inclusive.
- Negative for SARS-CoV-2 infection at the time of screening
- In generally good health, without significant medical illness
- Demonstrates comprehension of the protocol procedures and is able to provide written informed consent.
- Available for all planned visits and willing to complete all protocol defined procedures and assessments
- Body mass index between 17 and 30 kg/m2 at screening.
- Female subjects must have a negative pregnancy test at screening and before each vaccination and fulfill an acceptable method of birth control (per protocol)
Exclusion Criteria:
- Known previous exposure to SARS-CoV-2 or receipt of an investigational product for the prevention or treatment of COVID-19, middle east respiratory syndrome (MERS), or severe acute respiratory syndrome (SARS).
- Is in a current occupation with high risk of exposure to SARS-CoV-2
- Individuals with the following underlying medical conditions who are at higher risk (or might be at higher risk) of severe illness from COVID-19 per the CDC's guidance
- Donation or use of blood or blood products within 4 weeks prior to vaccination or planned donation during the study period.
- Diagnosed bleeding disorder or significant bruising or bleeding difficulties that could make blood draws problematic.
- Any condition that resulted in the absence or removal of the spleen.
- Positive HIV, HBsAg or HCV tests at the screening visit.
- Stool sample with occult blood at screening.
- Use of antiviral medications, including anti-retrovirals, or any prescriptive medications for the prevention of COVID-19 within 7 days before vaccination
- Use of antibiotics, proton pump inhibitors, H2 blockers or antacids or medications known to affect the immune function within 7 to 14 days before vaccination
- Regular use of nonsteroidal anti-inflammatory drugs, sulfonylureas, and angiotensin II blockers within 7 days before vaccination
- Acute disease within 72 hours prior to vaccination defined as the presence of a moderate or severe illness
- History of drug, alcohol or chemical abuse within 1 year of screening or positive urine drug screen for drugs of abuse at screening
- History of hypersensitivity or allergic reaction to any component of the investigational vaccine
- Administration of any investigational vaccine, drug or device within 8 weeks preceding vaccination
Any other condition that in the clinical judgment of the investigator would jeopardize the safety or rights of a subject participating in the trial, would render the subject unable to comply with the protocol or would interfere with the evaluation of the study endpoints.
For subjects being re-evaluated for participation in the VXA-CoV2-1.1-S boost substudy the following will also be exclusionary:
- Laboratory values outside the range of normal for platelet counts and the following coagulation tests: PT/INR, aPTT, fibrinogen, and D-dimer.
Any of the following history or conditions that may lead to higher risk of clotting events and/or thrombocytopenia:
e. Family or personal history of bleeding or thrombosis f. History of heparin-related thrombotic events, and/or receiving heparin treatments g. History of autoimmune or inflammatory disease h. Presence of any of the following conditions known to increase risk of thrombosis within 6 months prior to screening:
- Recent surgery other than removal/biopsy of cutaneous lesions
- Immobility (confined to bed or wheelchair for 3 or more successive days)
- Head trauma with loss of consciousness or documented brain injury
- Receipt of anticoagulants for prophylaxis of thrombosis
- Recent clinically significant infection
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Low Dose VXA-CoV2-1
Low dose (1E10 I.U.) of VXA-CoV2-1 oral tableted vaccine dispensed at Day 1.
A subset will also receive a second dose at Day 29
|
non replicating Ad5 adjuvanted oral tableted vaccine
|
Experimental: High Dose
High Dose (1E11 I.U.) of VXA-CoV2-1 oral tableted vaccine dispensed at Day 1
|
non replicating Ad5 adjuvanted oral tableted vaccine
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Frequency of solicited symptoms of reactogenicity
Time Frame: Day 1 through Day 8 post each immunization
|
Subject reported symptoms of local and systemic reactogenicity
|
Day 1 through Day 8 post each immunization
|
Grade of solicited symptoms of reactogenicity
Time Frame: Day 1 through Day 8 post each immunization
|
Subject reported symptoms of local and systemic reactogenicity
|
Day 1 through Day 8 post each immunization
|
Frequency of unsolicited adverse events
Time Frame: Day 1 through Day 29 post each immunization
|
Any adverse events observed or reported following vaccination
|
Day 1 through Day 29 post each immunization
|
Grade of unsolicited adverse events
Time Frame: Day 1 through Day 29 post each immunization
|
Any adverse events observed or reported following vaccination
|
Day 1 through Day 29 post each immunization
|
Frequency of serious adverse events (SAEs)
Time Frame: Day 1 through Day 390
|
Any adverse events reported following vaccination meeting definition of serious
|
Day 1 through Day 390
|
Frequency of medically-attended adverse events (MAAEs)
Time Frame: Day 1 through Day 390
|
Any adverse events reported following vaccination meeting definition of serious
|
Day 1 through Day 390
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
SARS-CoV-2 specific IgG/IgA
Time Frame: Day 1 through Day 390
|
SARS-CoV-2 specific IgG/IgA by enzyme-linked immunosorbent assay (ELISA)
|
Day 1 through Day 390
|
Neutralizing antibody titers to SARS-CoV-2
Time Frame: Day 1 through Day 390
|
serum based assay of Ab titers
|
Day 1 through Day 390
|
Antigen-specific IgG/IgA antibody secreting (ASCs)
Time Frame: Day 1 through Day 44
|
ASCs by ELISpot
|
Day 1 through Day 44
|
Th1/Th2 polarization
Time Frame: Day 1 through Day 44
|
Flow Cytometry
|
Day 1 through Day 44
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
SARS-CoV-2 specific IgG/IgA by enzyme-linked immunosorbent assay
Time Frame: Days 1, 29, 180 and 360
|
MSD
|
Days 1, 29, 180 and 360
|
Neutralizing antibody titers to SARS-CoV-2
Time Frame: Days 1, 29, 180 and 360
|
serum based assay of Ab titers
|
Days 1, 29, 180 and 360
|
Antigen-specific IgG/IgA antibody secreting assays (ASCs)
Time Frame: Days 1 and Day 8
|
ELISpot
|
Days 1 and Day 8
|
Plasmablast immunophenotyping
Time Frame: Day 1 and Day 8
|
Flow Cytometry
|
Day 1 and Day 8
|
Detection of antigen S-specific IgA
Time Frame: Day 1 and Day 8
|
Flow Cytometry
|
Day 1 and Day 8
|
Detection of antigen S-specific IgA
Time Frame: Days 1, 29, 180, and 360
|
Nasal swabs (SAM Device)
|
Days 1, 29, 180, and 360
|
Detection of antigen S-specific IgA
Time Frame: Days 1, 29, 180, and 360
|
Saliva
|
Days 1, 29, 180, and 360
|
Cytof analysis of cell populations
Time Frame: Day 1 and Day 8
|
Whole blood-based analysis
|
Day 1 and Day 8
|
IFN-g production/IL-4 production by T cells
Time Frame: Day 1 and Day 8
|
fresh whole blood/TrueCulture tube
|
Day 1 and Day 8
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- VXA-COV2-101
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Covid19
-
Anavasi DiagnosticsNot yet recruiting
-
Ain Shams UniversityRecruiting
-
Israel Institute for Biological Research (IIBR)Completed
-
Colgate PalmoliveCompleted
-
Christian von BuchwaldCompleted
-
Luye Pharma Group Ltd.Shandong Boan Biotechnology Co., LtdActive, not recruiting
-
University of ZurichLabor Speiz; Swiss Armed Forces; Universitätsspital ZürichEnrolling by invitation
-
Alexandria UniversityCompleted
-
Erasmus Medical CenterUniversity Medical Center Groningen; Academisch Medisch Centrum - Universiteit... and other collaboratorsRecruiting
Clinical Trials on VXA-CoV2-1
-
VaxartCompletedNorovirus InfectionsUnited States
-
VaxartCompletedSeasonal InfluenzaUnited States
-
VaxartCompleted
-
GlaxoSmithKlineCompletedVirus DiseasesUnited States
-
VaxartCompletedNorovirus InfectionUnited States
-
Centre Hospitalier Intercommunal CreteilAssociation Clinique Thérapeutique Infantile du val de Marne; GPIP; Francophone...Withdrawn
-
VaxartCompletedImmunogenicity & Safety Study of Adenovirus Type 5 (AD5) Based Oral Norovirus Vaccines (VXA-NVV-105)Norovirus InfectionsUnited States
-
VaxartCompletedSeasonal Influenza Preventative Vaccine PharmacodynamicsUnited States